anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.

Exclusion Criteria:

Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen
Intervention: ORFORGLIPRON
Trial phase: Phase 2
SMILES: Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion Criteria:

Have any prior diagnosis of diabetes
Have a prior or planned surgical treatment for obesity
Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
Have a history of acute chronic pancreatitis
Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

Have poorly controlled hypertension
Have history of acute myocardial infarction
Have history of cerebrovascular accident (stroke)
Had hospitalization due to congestive heart failure (CHF)
Have cancer
Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
Have hepatitis B and/or positive hepatitis B surface antigen